How to Navigate China Health Food Filing for Foreign Brands: 2026 Guide

Date:

Share post:






China Health Food Filing Guide 2026 | China Gateway 360


How to Navigate China Health Food Filing for Foreign Brands: 2026 Guide

1. Introduction — What Is Health Food Filing vs. Registration?

China’s health food market is one of the largest and fastest-growing in the world, valued at over ¥300 billion RMB and expanding at a compound annual growth rate of roughly 10%. For foreign brands looking to enter this lucrative market, understanding the regulatory pathway is the single most critical success factor. Since 2016, the China Food and Drug Administration (CFDA, now under the State Administration for Market Regulation — SAMR) has maintained a dual-track system for health food (保健食品, baojian shipin) market access: filing (备案, bei’an) and registration (注册, zhuce).

Key Takeaway: Filing (备案) is a simplified notification-based process for low-risk products with ingredients listed in the state directory. Registration (注册) is a full, scrutiny-heavy review required for novel ingredients, compounded formulas, or products not covered by the directory. Filing can be completed in 3–6 months; registration typically takes 12–24 months or longer.

Filing is analogous to a “fast track” for health food products. It was introduced by the 2016 revised Food Safety Law and subsequent implementing regulations (most notably the Health Food Filing and Registration Administrative Measures, or 保健食品注册与备案管理办法) to accelerate market entry for products with well-understood, low-risk ingredients. Registration, by contrast, subjects every aspect of a product to a rigorous pre-market evaluation — including safety, efficacy, quality, and manufacturing — by the SAMR’s expert committee.

For foreign brands, the filing route is almost always preferable when available. However, it is only open to products that fit within a tightly defined regulatory box. Understanding the boundaries of that box — and how to navigate the filing process efficiently — is the subject of this guide.

2. Eligibility: Which Product Categories Qualify for Filing

Not all health foods can use the filing track. Eligibility is determined primarily by the product’s ingredient composition and its dosage form. As of 2026, the following categories are eligible for health food filing:

2.1 Vitamin and Mineral Products

Single- and multi-vitamin and mineral supplements are the most common filing candidates. This includes products containing vitamins A, B-complex (B1, B2, B3/niacin, B5/pantothenic acid, B6, B7/biotin, B9/folate, B12), C, D, E, and K, as well as minerals such as calcium, magnesium, zinc, iron, selenium, copper, chromium, and iodine. Products must adhere to dosage limits specified in the national standards (GB 16740 and supplementary notices).

2.2 Select Botanical and Nutrient Ingredients

The Directory of Health Food Ingredients (保健食品原料目录) has been progressively expanded and now includes ingredients beyond vitamins and minerals. As of the 2024–2026 updates, the following non-vitamin/mineral substances are eligible for filing:

  • Coenzyme Q10 (CoQ10) — limited to 30–100 mg/day
  • Lycopene — 10–30 mg/day
  • Astaxanthin — 4–12 mg/day
  • Lutein — 6–20 mg/day
  • Phosphatidylserine — 100–300 mg/day
  • Gamma-aminobutyric acid (GABA) — 100–500 mg/day
  • Melatonin — 1–3 mg/day (for sleep improvement claims only)
  • Calcium lactate, calcium carbonate, and certain other mineral salts

2.3 Excluded Products

The following categories cannot use the filing track and must go through registration:

  • Products containing any ingredient not listed in the Directory
  • Compound formulas combining multiple botanical extracts beyond the permitted scope
  • Products making health function claims beyond those explicitly allowed for the ingredient (e.g., an unlisted functional claim for CoQ10)
  • Products in unconventional dosage forms (injectables, transdermal patches, etc.)
  • Imported products that have not been manufactured by a company with a valid Chinese manufacturing or trading license — though foreign brands can file as importers through a Chinese agent

3. The Filing Track vs. Registration Track: Key Differences

The strategic choice between filing and registration has profound implications for budget, timeline, and risk. The table below summarizes the key differences.

Dimension Filing (备案) Registration (注册)
Regulatory basis Self-declaration + post-market supervision Pre-market expert review & approval
Ingredients allowed Only those in the Directory Any ingredient with proven safety & efficacy
Approximate timeline 3–6 months 12–24 months (up to 36 months for complex products)
Total cost (RMB) 50,000–150,000 500,000–2,000,000+
Factory audit required No (document review only) Yes (on-site inspection for foreign manufacturers)
Clinical trial required No (literature safety data sufficient) Often required for novel ingredients
Filing/Approval number 国食健备 G + 4-digit year + 4-digit sequence 国食健注 G + 4-digit year + 4-digit sequence
Validity period No expiry (ongoing post-market compliance) 5 years (renewal required)
Post-market obligations Adverse event reporting, label compliance Same + renewal, change notifications, re-evaluation
Suitable for Standard vitamins, minerals, directory-listed ingredients Novel ingredients, herbal formulas, unique claims
Key Takeaway: If your product’s ingredients fall within the Directory of Health Food Ingredients, filing is overwhelmingly the better choice — faster, cheaper, and simpler. Registration should only be pursued when the nature of the product demands novel or combined ingredients unavailable through the directory.

4. Eligible Raw Materials: The Directory of Health Food Ingredients

The Directory of Health Food Ingredients (保健食品原料目录) is the single most important regulatory document for the filing track. It is maintained and periodically updated by the SAMR, with technical input from the China National Center for Food Safety Risk Assessment (CFSA).

As of mid-2026, the Directory includes approximately 60+ individual ingredients across two main categories:

4.1 Category 1: Nutrients

Vitamins (A through K, including all B-vitamin variants), minerals (calcium, magnesium, iron, zinc, selenium, copper, chromium, iodine, manganese, molybdenum, phosphorus, potassium, etc.), and certain amino acids (e.g., lysine, taurine). For each nutrient, the Directory specifies the daily dosage range and the permissible health function claim (e.g., “helps maintain bone health” for calcium and vitamin D).

4.2 Category 2: Non-Nutrient Functional Ingredients

These are bioactive compounds that have been formally recognized by the SAMR as safe and suitable for inclusion in filing-track products. The list has expanded significantly since the first edition (2016), with notable additions in the 2021, 2023, and 2025–2026 updates:

  • Coenzyme Q10 — antioxidant, supports cardiovascular health
  • Lycopene — antioxidant
  • Astaxanthin — antioxidant
  • Lutein — helps maintain vision health
  • Phosphatidylserine — helps improve memory and cognitive function
  • GABA (Gamma-aminobutyric acid) — helps relieve anxiety and improve sleep
  • Melatonin — improves sleep quality
  • Algae-sourced DHA — cognitive development in children
  • Algae-sourced EPA/DHA combinations (added 2025)
  • Resveratrol — antioxidant (pilot inclusion, 2026)

4.3 How to Verify Directory Status

Before initiating a filing application, foreign brands must verify that every single ingredient in their formula is listed in the Directory, and that the proposed daily dosage and health claim match the Directory’s specifications precisely. Verification can be done via:

  • The official SAMR online database (searchable by ingredient name)
  • The CFSA’s published lists and updates
  • Consultation with a licensed Chinese regulatory affairs firm or food safety consultant

If even one ingredient is absent from the Directory, the entire product is ineligible for filing and must proceed through registration.

5. Step-by-Step Filing Process

The health food filing process can be broken down into seven discrete stages. While the exact sequence may vary depending on the product and the appointing agent, the following represents the standard, proven workflow.

Step 1 Engage a Chinese Agent or Legal Entity
Foreign brands without a Chinese subsidiary must appoint a Chinese agent (a licensed food producer, trading company, or regulatory consulting firm) registered with the SAMR. The agent assumes legal responsibility for the product’s compliance in China. This step includes signing a notarized power of attorney and a quality agreement.
Step 2 Confirm Ingredient Eligibility
Cross-reference every ingredient and dosage against the Directory of Health Food Ingredients. If the product contains any non-directory ingredient, immediately pivot to registration or reformulate. Also verify that the proposed health function claim matches one of the approved claims for each ingredient.
Step 3 Prepare the Dossier
Compile all required documents (see Section 6 below). This is the most time-consuming part. Documents must be translated into Simplified Chinese by a certified translation provider. Foreign-language originals must be notarized. For imported products, manufacturing licenses and GMP certificates from the country of origin must be apostilled or consular-legalized (depending on the jurisdiction).
Step 4 Conduct Testing at Accredited Laboratories
Product samples must be tested at a SAMR-accredited testing laboratory in China. As the filing track does not require a factory audit, the lab will test the samples for: (a) hygiene indicators (heavy metals, microbial limits, pesticide residues), (b) active ingredient content, (c) stability (accelerated and long-term), and (d) functional indicators if applicable. Testing typically takes 6–10 weeks.
Step 5 Submit via the Online Filing System
The Chinese agent logs into the SAMR’s Health Food Filing Management System (保健食品备案管理系统) and uploads all documents in PDF format. The system performs an initial automated format check. If all required fields are completed, the application enters the review queue.
Step 6 Review and Correction (If Needed)
SAMR officials review the submission within 30 working days. If corrections or clarifications are needed, the system issues a Notice of Supplementation. Applicants typically have 60 days to respond. Common correction requests include missing translations, unclear manufacturing process descriptions, or insufficient stability data.
Step 7 Receive Filing Number and Certificate
Once the review is satisfactory, the SAMR issues a Health Food Filing Certificate (保健食品备案凭证) and a 12-character filing number starting with 国食健备 G. The product is now legally authorized for manufacture (or import) and sale in China. The entire process, from dossier preparation to certificate issuance, typically takes 3 to 6 months.

6. Required Documents

The filing dossier must contain a comprehensive set of technical and administrative documents. The following checklist covers the typical requirements for foreign brands:

Document Description Notes for Foreign Brands
1. Product Formula Complete list of all ingredients, including excipients, with percentages and dosage per serving Must match the label; Chinese INCI names required
2. Manufacturing Process Detailed description of production steps, critical control points, equipment used Must be translated and notarized; GMP certificate required
3. Quality Standards Specification sheets for raw materials and finished product, including test methods Reference China Pharmacopoeia (ChP) or GB standards where applicable
4. Stability Report Accelerated (6 months at 40°C/75% RH) and long-term (24 months at 25°C/60% RH) stability data Tests must be conducted at a CNAS/CMA-accredited lab
5. Safety Assessment Report Comprehensive safety evaluation using toxicological data, literature review, and ingredient safety profiles For directory ingredients, a literature-based safety assessment is sufficient
6. Hygiene Test Report Heavy metals (Pb, As, Hg, Cd), microbial limits, pesticide residues, solvent residues Must be from a Chinese SAMR-accredited lab
7. Label and Packaging Proofs Chinese-language label, instructions, and packaging mock-ups Must comply with GB 7718 and GB 16740; claim text must match directory-approved wording
8. Legal Documents Business license, GMP certificate, manufacturing license, power of attorney Foreign documents require notarization, apostille/consular legalization, and Chinese translation
9. Sample Product Commercial-scale production samples (typically 3 batches, 10x full pack size each) Shipped to the Chinese agent for testing and archiving

All documents must be submitted in Simplified Chinese. Original foreign-language documents must be accompanied by a certified Chinese translation. For imported products, the Certificate of Free Sale (CFS) and GMP certificate from the country of origin are normally required.

7. Testing Requirements

Testing is a non-negotiable part of the filing process, and it must be conducted at SAMR-accredited laboratories in China. The following testing categories apply:

7.1 Hygiene Tests

Every health food product must pass limits for heavy metals (lead ≤ 2.0 mg/kg, arsenic ≤ 1.0 mg/kg, mercury ≤ 0.3 mg/kg, cadmium ≤ 0.5 mg/kg for most products), microbial contaminants (total bacterial count ≤ 1,000 CFU/g for solid forms, ≤ 500 CFU/mL for liquids; coliforms, mold, yeast, Salmonella, and Staphylococcus aureus), and pesticide residues (BHC, DDT, and others as applicable).

7.2 Content/Quantification Tests

The active ingredient content must be verified using validated analytical methods. For vitamin and mineral products, the measured content must fall within 100% ± 20% of the declared value. For functional ingredients like CoQ10 or melatonin, tighter tolerances (typically 100% ± 10%) apply.

7.3 Stability Tests

Two types of stability studies are required:

  • Accelerated stability: 6 months at 40°C ± 2°C / 75% RH ± 5% RH
  • Long-term stability: 24 months at 25°C ± 2°C / 60% RH ± 5% RH

Samples are tested at 0, 1, 2, 3, and 6 months (accelerated) and 0, 3, 6, 9, 12, 18, and 24 months (long-term). Degradation products, appearance, hardness, dissolution, and preservative efficacy are monitored.

7.4 Functional Tests

For directory-listed ingredients, separate functional tests (e.g., animal studies or human trials) are not required. The health claim is granted based on the ingredient’s inclusion in the Directory and conformance with its specified dosage. However, if the product makes a claim that differs from the Directory’s pre-approved claim language, the applicant must provide supporting evidence — which effectively pushes the product back into registration territory.

Practical Tip: Begin stability testing early — it is the longest pole in the tent. Accelerated stability alone takes 6 months. If you are developing a new product for the Chinese market, start the stability study as soon as the pilot batch is produced, and prepare the rest of the dossier while the stability clock is running.

8. Timeline: Filing vs. Registration

Time-to-market is one of the strongest arguments in favor of the filing route. Below is a realistic timeline breakdown for each pathway.

Stage Filing (备案) Registration (注册)
Dossier preparation & translation 4–8 weeks 8–16 weeks
Product testing 8–12 weeks 12–20 weeks
Stability testing 24–28 weeks (can run in parallel) 24–52 weeks (longer for novel ingredients)
SAMR review 4–8 weeks 20–52 weeks (including expert committee review & possible supplemental submissions)
Factory audit (if applicable) Not required 8–12 weeks (scheduling + travel + report)
Total (best case) ~3 months ~12 months
Total (realistic) 4–6 months 18–24 months (up to 36 months for complex products)

The key strategic insight: because stability testing (6 months accelerated) is the longest fixed-duration step for filing, a well-prepared applicant can complete the rest of the process during that window, achieving a total end-to-end timeline of approximately 6–8 months from project kickoff to filing number. Registration applicants should budget at least 18 months and plan for at least one round of supplemental submissions, each of which can add 2–4 months.

9. Costs: Filing vs. Registration

The cost differential between filing and registration is dramatic. The table below provides estimated all-in costs in RMB, including consultant fees, testing, translation, notarization, and SAMR administrative fees (where applicable).

Cost Item Filing (RMB) Registration (RMB)
Regulatory consulting & agent fees 20,000–40,000 100,000–400,000
Product testing (hygiene + content) 10,000–20,000 20,000–50,000
Stability testing (accelerated + long-term) 15,000–30,000 30,000–80,000
Functional testing / clinical trials Not required (¥0) 200,000–1,000,000+
Translation, notarization, legalization 5,000–15,000 15,000–50,000
SAMR administrative / review fees ¥0 (filing is free) 8,000–20,000
Factory audit (travel + interpretation) Not required (¥0) 50,000–150,000
Contingency / supplementary submissions 5,000–10,000 50,000–200,000
Total estimated range 50,000–150,000 RMB 500,000–2,000,000+ RMB
Key Takeaway: Filing costs roughly 10–25% of registration. For a foreign brand bringing a standard vitamin or CoQ10 product to market, the total investment for filing is approximately $7,000–$20,000 USD, compared to $70,000–$280,000+ USD for registration. This cost advantage, combined with the faster timeline, makes filing the obvious choice for qualifying products.

10. Post-Filing Obligations

Obtaining a health food filing certificate is not the end of the regulatory journey. Foreign brands and their Chinese agents must remain vigilant about ongoing compliance obligations.

10.1 Label and Packaging Compliance

All marketed products must bear the official Health Food Logo (蓝帽子, Blue Hat) — a blue cap-shaped icon with “保健食品” (Health Food) text. The label must include the following, in Simplified Chinese:

  • Product name and filing number
  • Ingredients list (descending order by weight)
  • Net content and serving size
  • Health function claim (verbatim from the Directory)
  • Target population (e.g., “suitable for adults with…”)
  • Storage conditions and shelf life
  • Distributor / manufacturer name and address in China
  • The mandatory warning: “本品不能代替药物” (This product cannot replace medication)

10.2 Adverse Event Reporting

Filing holders are required to establish an adverse event monitoring system and report any serious adverse events to the local SAMR office within 24 hours. Non-serious events must be reported quarterly. Failure to comply can result in suspension of sales and fines.

10.3 Changes and Amendments

The following changes require a new filing submission (not just a notification):

  • Change to the product formula (any ingredient addition, removal, or dosage change)
  • Change in manufacturing process or manufacturing site
  • Change in the proposed health function claim
  • Change in product name

Minor changes (e.g., packaging design updates, distributor information) can be handled through the online system with a notification and updated documents.

10.4 Renewal

Unlike registration (which expires after 5 years), the filing certificate has no fixed expiry. However, the SAMR may conduct post-market surveillance reviews at any time. If the regulatory landscape changes — such as an ingredient being removed from the Directory or a new dosage limit being imposed — the filing holder may be required to update their filing or cease production. Periodic surveillance testing (every 1–2 years) is strongly recommended.

10.5 Market Recall Obligations

Filing holders must have a product recall plan in place. If a quality defect, contamination, or labeling violation is identified, the company must initiate a recall within 48 hours and report to the SAMR. The regulation applies equally to imported products — the Chinese agent bears on-the-ground recall responsibility.

11. 2026 Updates: Expanded Directory, Simplified Procedures

The China health food regulatory environment has been steadily evolving, and 2026 brings several notable changes that benefit foreign brands pursuing the filing track.

11.1 Expanded Ingredient Directory

The 2025–2026 round of Directory updates added the following new ingredients and expanded dosage ranges for existing entries:

  • Algae-sourced DHA + EPA — now permitted as a combination for the first time, with a maximum daily intake of 1,000 mg (EPA+DHA combined). Previously, only algae DHA as a standalone ingredient was allowed. This opens the door for plant-based omega-3 supplements to use the filing track.
  • Resveratrol — included as a pilot ingredient at 50–200 mg/day, with the health claim limited to “antioxidant.” This is a significant development for the anti-aging supplement segment.
  • Vitamin K2 (menaquinone-7, MK-7) — added at 45–100 μg/day for bone health claims. Previously, vitamin K for filing was limited to K1 (phylloquinone).
  • Increased dosage ceilings for several minerals — including zinc (now up to 15 mg/day) and magnesium (up to 300 mg/day), reflecting updated nutritional science.

11.2 Simplified Online Submission Process

In early 2026, the SAMR rolled out a fully digital filing platform that eliminates the need for physical document submission. Key improvements include:

  • Real-time application status tracking (previously opaque)
  • Automated format validation that flags missing or non-compliant sections before submission
  • Digital signatures accepted (e-signature recognition for Chinese legal entities; foreign entities may still require a wet signature)
  • Reduced review time from 30 to 20 working days for applications that pass the automated pre-check

11.3 Pilot Self-Declaration for Low-Risk Products

A new pilot program launched in Shenzhen, Shanghai, and Hainan Free Trade Port allows self-declaration filing for single-ingredient vitamin and mineral products. Under this program, qualified applicants can submit a streamlined dossier (product information + test report only) and begin marketing immediately, subject to a post-market audit within 60 days. If the pilot is successful, it may expand nationwide in 2027.

11.4 Enhanced Post-Market Surveillance

To balance the fast-track filing system, the SAMR has significantly increased post-market surveillance activities in 2026. Random sampling and testing rates for filing-track products have risen from ~3% to ~8% of products annually. Foreign brands should ensure their Chinese agents maintain complete quality records and sample archives for at least 5 years.

2026 Outlook: The overall trend is unequivocally positive for foreign brands. The Directory is expanding, procedures are digitizing, and the regulatory mindset is shifting from “pre-market control” to “post-market risk management.” However, with faster entry comes tighter post-market scrutiny. Brands that invest in robust quality systems and Chinese-language compliance documentation will have a durable competitive advantage.

12. Conclusion & Practical Advice

China’s health food market offers enormous opportunity for foreign brands, but the regulatory pathway is a make-or-break factor. The dual-track system of filing (备案) and registration (注册) gives brand owners a clear strategic choice: filing for speed and cost efficiency if the product fits in the box, or registration for flexibility and differentiation if it does not.

12.1 Who Should Choose Filing?

The filing track is ideal for foreign brands that:

  • Offer standard vitamin, mineral, or Directory-listed functional ingredients (CoQ10, lutein, astaxanthin, etc.)
  • Want to test the Chinese market quickly and at low cost (under $20,000 USD)
  • Are introducing a product that already has sales in other regulated markets (US, EU, Japan, Australia) with established safety data
  • Have limited in-house regulatory affairs resources in China

12.2 Common Pitfalls to Avoid

  • Assuming all natural ingredients are “Directory-listed”: Many common dietary supplement ingredients (e.g., milk thistle/silymarin, echinacea, ginseng, green tea extract, probiotics) are not in the Directory and require registration. Always verify before committing to a filing strategy.
  • Underestimating translation and legalization timelines: Getting documents notarized, apostilled/legalized, and professionally translated can take 4–6 weeks. Plan accordingly.
  • Choosing the wrong Chinese agent: The agent is legally responsible for your product’s compliance. Choose a firm with proven health food filing experience, not a general trade agent. Check references and ask for examples of successful filings.
  • Overclaiming health functions: The SAMR strictly enforces claim language. If the Directory says “antioxidant” for CoQ10, you cannot claim “heart health” or “energy support” without additional registration.
  • Neglecting post-market obligations: The filing certificate may not expire, but ongoing compliance is mandatory. Set up an adverse event reporting system and maintain quality records from day one.

12.3 Strategic Recommendations for 2026

  1. Start with a regulatory audit: Have a qualified consultant review your product formula against the Directory before making any decision. This 1–2 week audit (costing approximately ¥10,000–20,000) can save months and hundreds of thousands of RMB.
  2. Engage a Chinese lab early: Begin discussions with a SAMR-accredited lab during the product development phase. They can advise on formulation adjustments to improve stability outcomes and ensure test method compatibility.
  3. Monitor the Directory closely: The ingredient list is expanding rapidly. If your product contains an ingredient that is “near inclusion” (resveratrol-level), consider filing a placeholder application for a simpler product while waiting for the Directory update.
  4. Leverage the pilot programs: If your target consumer base is in Shenzhen, Shanghai, or Hainan, explore the self-declaration pilot for single-ingredient products. This could reduce your timeline to 8–12 weeks.
  5. Partner with a domestic distributor: Instead of filing as a foreign entity through an agent, consider establishing a WFOE (Wholly Foreign-Owned Enterprise) in China that can act as the legal filing entity. This gives you direct control over the compliance process and the Chinese brand.
  6. Build post-market compliance capacity: With enhanced surveillance in 2026, invest in a Chinese-language quality management system (QMS) and designate a local compliance officer. This is not optional — it is a regulatory requirement.

China’s health food regulatory system is neither arbitrary nor insurmountable — it is structured, predictable, and increasingly aligned with international best practices. The filing track, in particular, is a well-lit, fast, and affordable path for the right products. By understanding the rules, preparing thoroughly, and working with experienced in-country partners, foreign brands can successfully bring their health food products to the world’s most dynamic nutrition market.

Final Takeaway: The health food filing system in China is a genuine opportunity — not a barrier — for foreign brands with Directory-compliant products. At 3–6 months and 50,000–150,000 RMB, it is one of the most cost-effective regulatory pathways for dietary supplements anywhere in the major markets globally. The 2026 updates make it even more attractive. The brands that act now, with professional preparation, will be well-positioned to capture meaningful market share in China’s ¥300+ billion health food industry.

Disclaimer: This guide is for informational purposes only and does not constitute legal or regulatory advice. Regulatory requirements may change. Brands should consult with qualified Chinese regulatory affairs professionals before initiating any filing or registration process.

© 2026 China Gateway 360 — Your Bridge to the Chinese Market. All rights reserved. | Article ID: CG360-HEALTH-SUPPLEMENTS-GUID-003

Keywords: China health food filing, 保健食品备案, SAMR, Directory of Health Food Ingredients, foreign brands China supplement registration, 2026 health food regulations


Related articles

How a Foreign Biotech Startup Entered China’s Precision Medicine Market: Case Study

How a Foreign Biotech Startup Entered China's Precision Medicine Market: Case Study In 2023, NovaOnco Therapeutics, a US-based AI biotech startup, exe

How Legend Biotech Secured FDA Approval for CAR-T Therapy: Case Study

How Legend Biotech Secured FDA Approval for CAR-T Therapy: A China Biotech Case Study This case study examines how Legend Biotech (传奇生物, Legend Biotec

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study

How Innovent Biologics Achieved Global Clinical Trial Leadership: Case Study body{font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;line-height:

How BeiGene Built a Billion-Dollar Biotech in China: Case Study

How BeiGene Built a Billion-Dollar Biotech in China: Case Study How BeiGene Built a Billion-Dollar Biotech in China: Case Study The story of BeiGene's